Skip to content
ChickenStockChickenStock
ResearchNRIX
Nurix Therapeutics logo

Nurix Therapeutics (NRIX) stock

NASDAQ

$15.46-0.87%(-0.14)

As of the Nov 13, 2026 close (U.S. Eastern)

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

5.73x

P/B

1.74x

P/S

2.40x

Latest earnings

SEC filings

Jun–Aug 2026(FY2026 Q3)

Revenue increased 8,312.5% from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Oct 13, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

40 SEC filings
  • van Houte HansChief Financial Officer · Nov 4, 2026Open-market sale4,769 shares · $75K
    Avg. price $15.6348
    Show 2 price lots
    • 3,300 shares × $15.3824$51K
    • 1,469 shares × $16.2018$24K
  • Ring ChristineChief Legal Officer · Nov 3, 2026Open-market sale6,113 shares · $158K
    Avg. price $25.83294,406 shares held after
  • Ring ChristineChief Legal Officer · Nov 2, 2026Open-market sale10,602 shares · $274K
    Avg. price $25.843
    Show 2 price lots
    • 9,527 shares × $25.7392$245K
    • 1,075 shares × $26.7628$29K
  • Hansen GwennChief Scientific Officer · Nov 2, 2026Open-market sale1,452 shares · $39K
    Avg. price $26.8123,452 shares held after
  • Ring ChristineChief Legal Officer · Nov 2, 2026Option exercise5,786 shares · $50K
    Avg. price $8.7221,121 shares held after
  • Hansen GwennChief Scientific Officer · Nov 2, 2026Option exercise1,452 shares · $3K
    Avg. price $1.86124,904 shares held after
  • Hansen GwennChief Scientific Officer · Oct 30, 2026Open-market sale3,957 shares · $104K
    Avg. price $26.2791123,452 shares held after
  • Ring ChristineChief Legal Officer · Oct 30, 2026Open-market sale3,957 shares · $104K
    Avg. price $26.279115,335 shares held after
  • van Houte HansChief Financial Officer · Oct 30, 2026Open-market sale2,834 shares · $74K
    Avg. price $26.279147,514 shares held after
  • van Houte HansChief Financial Officer · Oct 30, 2026Option exercise10,182 shares · $0
    Avg. price $0
    Show 3 price lots
    • 2,859 shares × $0$0
    • 3,573 shares × $0$0
    • 3,750 shares × $0$0
  • Hansen GwennChief Scientific Officer · Oct 30, 2026Option exercise10,182 shares · $0
    Avg. price $0
    Show 3 price lots
    • 3,573 shares × $0$0
    • 2,859 shares × $0$0
    • 3,750 shares × $0$0
  • Ring ChristineChief Legal Officer · Oct 30, 2026Option exercise10,182 shares · $0
    Avg. price $0
    Show 3 price lots
    • 3,573 shares × $0$0
    • 2,859 shares × $0$0
    • 3,750 shares × $0$0
  • Hansen GwennChief Scientific Officer · Oct 15, 2026Open-market sale1,452 shares · $36K
    Avg. price $25117,227 shares held after
  • Hansen GwennChief Scientific Officer · Oct 15, 2026Option exercise1,452 shares · $3K
    Avg. price $1.86118,679 shares held after
  • GREGORY JULIA PDirector · Oct 14, 2026Open-market sale22,583 shares · $529K
    Avg. price $23.403810,750 shares held after
  • GREGORY JULIA PDirector · Oct 14, 2026Option exercise22,583 shares · $42K
    Avg. price $1.8633,333 shares held after
  • Ring ChristineChief Legal Officer · Oct 2, 2026Open-market sale5,786 shares · $134K
    Avg. price $23.18519,110 shares held after
  • Ring ChristineChief Legal Officer · Oct 2, 2026Option exercise5,786 shares · $50K
    Avg. price $8.7214,896 shares held after
  • Ring ChristineChief Legal Officer · Sep 2, 2026Open-market sale5,787 shares · $149K
    Avg. price $25.7599
    Show 2 price lots
    • 5,387 shares × $25.6947$138K
    • 400 shares × $26.6375$11K
  • Ring ChristineChief Legal Officer · Sep 2, 2026Option exercise5,787 shares · $50K
    Avg. price $8.7214,897 shares held after
  • Hansen GwennChief Scientific Officer · Sep 1, 2026Open-market sale1,452 shares · $37K
    Avg. price $25.47117,227 shares held after
  • Hansen GwennChief Scientific Officer · Sep 1, 2026Option exercise1,452 shares · $3K
    Avg. price $1.86118,679 shares held after
  • Hansen GwennChief Scientific Officer · Aug 5, 2026Open-market sale4,356 shares · $109K
    Avg. price $25117,227 shares held after
  • Hansen GwennChief Scientific Officer · Aug 5, 2026Option exercise4,356 shares · $8K
    Avg. price $1.86121,583 shares held after
  • van Houte HansChief Financial Officer · Aug 4, 2026Open-market sale4,761 shares · $116K
    Avg. price $24.3624
    Show 2 price lots
    • 2,967 shares × $24.6474$73K
    • 1,794 shares × $23.8911$43K
  • Hansen GwennChief Scientific Officer · Aug 4, 2026Open-market sale4,111 shares · $100K
    Avg. price $24.3594
    Show 2 price lots
    • 2,611 shares × $24.6415$64K
    • 1,500 shares × $23.8684$36K
  • Ring ChristineChief Legal Officer · Aug 3, 2026Open-market sale16,589 shares · $382K
    Avg. price $23.04899,110 shares held after
  • Ring ChristineChief Legal Officer · Aug 3, 2026Option exercise5,787 shares · $50K
    Avg. price $8.7225,699 shares held after
  • Ring ChristineChief Legal Officer · Jul 30, 2026Open-market sale3,847 shares · $90K
    Avg. price $23.382819,912 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Nurix Therapeutics (NRIX) stock information

NASDAQ

Nurix Therapeutics (NRIX) is listed on NASDAQ. Its market capitalization is about $1.7B. On trailing-twelve-month earnings the P/E ratio is 5.73, and the P/B ratio is 1.74. Return on equity is 30.4%. These figures are computed in-house from official filings and are reference information only.

Nurix Therapeutics — frequently asked questions

What is the P/E ratio of Nurix Therapeutics (NRIX)?
On a trailing-twelve-month basis, NRIX trades at a P/E ratio of 5.73. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Nurix Therapeutics?
NRIX has a market capitalization of about $1.7B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.